Gastroparesis Drug Market Size & Share Analysis - Growth Trends & Forecasts (2025 - 2030)

The Gastroparesis Drug Market Report Segments the Industry Into by Drug Class (Antiemetic Agents, Prokinetic Agents, Botulinum Toxin Injections, and Others), by Disease Type (Diabetic Gastroparesis, Post-Surgical Gastroparesis, Idiopathic Gastroparesis, and More), by End User (Hospitals, Specialty Clinics, Pharmacies), and Geography. The Market Sizes and Forecasts are Provided in Terms of Value (USD).

Global Gastroparesis Drug Market Size and Share

Image © Mordor Intelligence. Reuse requires attribution under CC BY 4.0.

Compare market size and growth of Global Gastroparesis Drug Market with other markets in Healthcare Industry

Global Gastroparesis Drug Market Analysis by Mordor Intelligence

The gastroparesis drugs market reached USD 5.03 billion in 2025 and is expected to climb to USD 6.30 billion by 2030, translating into a 4.6% CAGR during the forecast period. This outlook reflects a therapeutic field shaped by limited FDA-approved options, frequent off-label prescribing, and regulatory hurdles that slow the entry of novel agents. Metoclopramide remains the only oral drug formally cleared for gastroparesis, yet Evoke Pharma’s GIMOTI nasal spray shows how differentiated delivery can unlock demand, with annual run-rate sales topping USD 10 million in 2024. Prokinetic agents held 42.35% of the gastroparesis drugs market in 2024, but botulinum toxin injections are expanding fastest at 5.25% through 2030, mirroring growth in interventional gastroenterology procedures. North America dominated with a 43.81% share in 2024, supported by specialized care centers, while Asia-Pacific is projected to grow 6.41% a year to 2030 on the back of rising diabetes prevalence and broader healthcare access. Investor interest has rebounded, illustrated by CinDome Pharma’s USD 40 million Series B in 2024 to advance deudomperidone, a next-generation prokinetic that aims to improve cardiac safety.

Key Report Takeaways

  • By drug class, prokinetics led with 42.35% revenue share in 2024; botulinum toxin injections are forecast to advance at a 5.25% CAGR to 2030.
  • By disease type, diabetic gastroparesis held 60.25% of the gastroparesis drugs market share in 2024, while post-surgical cases are expected to expand at a 5.81% CAGR through 2030.
  • By end user, hospitals accounted for 48.18% of the gastroparesis drugs market size in 2024, and pharmacies are projected to grow at 6.14% CAGR between 2025 and 2030.
  • By geography, North America captured 43.81% revenue share in 2024; Asia-Pacific is set to post the fastest 6.41% CAGR during the forecast period.
  • Evoke Pharma, Renexxion, and CinDome Pharma together controlled a combined 18% of prescription sales in 2024, illustrating a moderately consolidated competitive field.

Segment Analysis

By Drug Class: Prokinetics Maintain Primacy amid Safety Innovation

Prokinetics captured 42.35% of the gastroparesis drugs market in 2024 and continue to anchor first-line therapy despite legacy safety warnings. GIMOTI’s 126% prescription growth in 2024 shows that nasal delivery can revitalize established molecules. Deudomperidone and naronapride are positioned to lift the gastroparesis drugs market size for this class through safer receptor selectivity and improved absorption. Botulinum toxin injections, while holding a smaller base, are rising 5.25% per year as gastroenterologists refine endoscopic pyloric injection techniques, improving symptom relief durability.

Antiemetics such as ondansetron sustain demand for nausea control, while extended-release granisetron is gaining traction in peri-operative settings. The “Others” basket ranges from mirtazapine in refractory cases to ghrelin receptor agonists like TZP-102, which normalized gastric emptying in 52.6% of diabetic patients in a Phase 2 study. This pipeline diversification underscores a trend toward etiology-tailored regimens that combine motility agents with symptom modulators.

Image © Mordor Intelligence. Reuse requires attribution under CC BY 4.0.

Note: Segment shares of all individual segments available upon report purchase

By Disease Type: Diabetic Dominance with Post-Surgical Upside

Diabetic gastroparesis accounted for 60.25% of cases and remains the primary revenue engine for the gastroparesis drugs market. However, the segment is complicated by wider GLP-1 agonist use, which may slow gastric emptying and heighten demand for rescue prokinetics. The gastroparesis drugs market share held by post-surgical presentations is small today yet expanding at a 5.81% CAGR as bariatric procedure volumes rise and clinicians implement structured follow-up protocols.

Idiopathic cases challenge standard care and spur research into inflammatory and neurogenic mechanisms. Viral and neurologic etiologies require nuanced approaches, including immunomodulators or neuroprotective agents. Medication-induced forms are becoming more visible in older adults on polypharmacy schedules, highlighting the need for drug-interaction-aware management pathways.

By End User: Hospitals Anchor Care while Pharmacies Expand

Hospitals held 48.18% of 2024 revenue thanks to diagnostic imaging, gastric scintigraphy, and implantable gastric stimulator procedures that remain inpatient tasks. The gastroparesis drugs market size tied to hospital utilization is set to grow steadily as combined device-drug regimens become common practice FDA. Specialty clinics are emerging centers of excellence, offering integrated dietary, psychological, and interventional services that shorten time to therapy optimization.

Pharmacies are projected to post 6.14% CAGR through 2030, reflecting broader chronic-care management, a rise in mailed specialty prescriptions, and home-based enteral nutrition that relies on pharmacy distribution channels [3]James F. Carmody, “Enteral Nutrition in Chronic Gastroparesis,” Journal of Nutritional Oncology, jnsonline.org. GIMOTI’s cold-chain handling and patient-education needs fit well with specialty pharmacy capabilities, creating an incremental driver for this channel.

Market Share
Image © Mordor Intelligence. Reuse requires attribution under CC BY 4.0.

Note: Segment shares of all individual segments available upon report purchase

Geography Analysis

North America accounted for 43.81% of 2024 revenue, anchored by large academic medical centers and favorable reimbursement for procedure-drug combinations. FDA designation of gastroparesis as an unmet medical need supports accelerated review for new entrants. The Cleveland Clinic reported 82% clinical response when combining gastric electrical stimulation with pyloromyotomy, reinforcing the region’s leadership in integrated care models. However, the tradipitant rejection shows that regulatory thresholds remain stringent.

Europe follows with a smaller but mature base. EMA guidelines and divergent national formularies lengthen rollout times, yet Germany showcases innovation through botanical combination therapy Iberogast Advance, supported by post-marketing data. Cross-border academic collaborations, such as Dr. Falk Pharma and Renexxion’s clinical partnership on naronapride, sustain a flow of late-stage assets. Professional societies, including the European Society of Neurogastroenterology and Motility, issue prescribing recommendations that shape clinical adoption.

Asia-Pacific is the fastest-growing region at 6.41% CAGR, propelled by high diabetes incidence, rapid urbanization, and expanding diagnostic capacity. Prevalence studies from Pakistan and Palestine highlight sizable undiagnosed populations, pointing to latent demand Cureus. Regulators in markets such as South Korea now grant reimbursement for new acid-suppressive agents that can be co-administered with prokinetics, signaling greater openness to novel gastrointestinal therapies. Pharmaceutical alliances, including the Lupin–Takeda tie-up for vonoprazan in India, illustrate the value multinationals place on regional partnerships to navigate pricing and distribution complexities.

Gastroparesis Drug Market
Image © Mordor Intelligence. Reuse requires attribution under CC BY 4.0.

Competitive Landscape

The gastroparesis drugs market features moderate concentration, with the top five suppliers controlling nearly 45% of prescription revenue in 2024. Evoke Pharma leveraged a differentiated nasal formulation to gain rapid uptake, achieving an annual run rate above USD 10 million within four years of launch. Renexxion focuses on dual-mechanism prokinetics, while CinDome Pharma applies deuterium chemistry to enhance cardiac safety. Each firm partners strategically for geographic reach: Renexxion with Dr. Falk in Europe and CinDome exploring out-licensing in Asia-Pacific.

Pipeline intensity is rising as investors recognize unmet need. Midsize firms and academic spin-outs concentrate on receptor-specific compounds, ghrelin agonists, and serotonin modulators that target distinct gastroparesis subtypes. Device makers are also entering the competitive mix; gastric electrical stimulator suppliers collaborate with drug developers to bundle procedural and pharmaceutical solutions, boosting switching costs for clinicians and payers.

Large multinationals participate selectively, often through licensing rather than internal R&D, preferring risk-managed exposure while monitoring safety outcomes from novel agents. This dynamic leaves room for nimble entrants to secure orphan indications, pediatric extensions, and real-world evidence packages that strengthen access negotiations with payers.

Global Gastroparesis Drug Industry Leaders

  1. Evoke Pharma

  2. AstraZeneca

  3. Cadila Pharmaceuticals

  4. Neurogastrx, Inc.

  5. AbbVie Inc. ( Allergan Plc)

  6. *Disclaimer: Major Players sorted in no particular order
Gastroparesis Drug Market Concentration
Image © Mordor Intelligence. Reuse requires attribution under CC BY 4.0.
Need More Details on Market Players and Competitors?
Download PDF

Recent Industry Developments

  • January 2025: Entero Therapeutics agreed to a reverse merger with Journey Therapeutics to form a Nasdaq-listed entity focused on gastrointestinal diseases, including capeserod for gastroparesis.
  • September 2024: Lupin and Takeda partnered to commercialize vonoprazan in India, broadening the acid-disorder portfolio relevant to overlap cases of gastroparesis and reflux.
  • May 2024: CinDome Pharma raised USD 40 million in Series B funding to advance deudomperidone clinical trials targeting diabetic gastroparesis.
  • March 2024: Dr. Falk Pharma gained FDA IND clearance for naronapride, enabling United States studies of this selective prokinetic.

Table of Contents for Global Gastroparesis Drug Industry Report

1. Introduction

  • 1.1 Study Assumptions & Market Definition
  • 1.2 Scope of the Study

2. Research Methodology

3. Executive Summary

4. Market Landscape

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Rising incidence of diabetes
    • 4.2.2 Increase in gastric & bariatric surgeries
    • 4.2.3 Growing geriatric population
    • 4.2.4 New approvals of novel prokinetics
    • 4.2.5 Adoption of gastric electrical stimulators boosting adjunct drug use
    • 4.2.6 Expansion of home-based enteral nutrition programs
  • 4.3 Market Restraints
    • 4.3.1 Lengthy regulatory approval timelines
    • 4.3.2 Adverse effects & product withdrawals
    • 4.3.3 Shift toward cannabinoid & herbal alternatives
    • 4.3.4 Limited reimbursement for idiopathic cases
  • 4.4 Value / Supply-Chain Analysis
  • 4.5 Regulatory Landscape
  • 4.6 Technological Outlook
  • 4.7 Porter’s Five Forces Analysis
    • 4.7.1 Threat of New Entrants
    • 4.7.2 Bargaining Power of Buyers
    • 4.7.3 Bargaining Power of Suppliers
    • 4.7.4 Threat of Substitutes
    • 4.7.5 Competitive Rivalry

5. Market Size & Growth Forecasts (Value)

  • 5.1 By Drug Class
    • 5.1.1 Antiemetic Agents
    • 5.1.1.1 5-HT3 Antagonists
    • 5.1.1.2 NK-1 Antagonists
    • 5.1.1.3 Dopamine Antagonists
    • 5.1.2 Prokinetic Agents
    • 5.1.2.1 Metoclopramide
    • 5.1.2.2 Domperidone
    • 5.1.2.3 Macrolide Antibiotics
    • 5.1.2.4 Ghrelin Receptor Agonists
    • 5.1.3 Botulinum Toxin Injections
    • 5.1.4 Others
  • 5.2 By Disease Type
    • 5.2.1 Diabetic Gastroparesis
    • 5.2.2 Post-Surgical Gastroparesis
    • 5.2.3 Idiopathic Gastroparesis
    • 5.2.4 Viral & Neurological-Induced Gastroparesis
    • 5.2.5 Others
  • 5.3 By End User
    • 5.3.1 Hospitals
    • 5.3.2 Specialty Clinics
    • 5.3.3 Pharmacies
  • 5.4 By Geography
    • 5.4.1 North America
    • 5.4.1.1 United States
    • 5.4.1.2 Canada
    • 5.4.1.3 Mexico
    • 5.4.2 Europe
    • 5.4.2.1 Germany
    • 5.4.2.2 United Kingdom
    • 5.4.2.3 France
    • 5.4.2.4 Italy
    • 5.4.2.5 Spain
    • 5.4.2.6 Rest of Europe
    • 5.4.3 Asia-Pacific
    • 5.4.3.1 China
    • 5.4.3.2 Japan
    • 5.4.3.3 India
    • 5.4.3.4 Australia
    • 5.4.3.5 South Korea
    • 5.4.3.6 Rest of Asia-Pacific
    • 5.4.4 Middle East & Africa
    • 5.4.4.1 GCC
    • 5.4.4.2 South Africa
    • 5.4.4.3 Rest of Middle East & Africa
    • 5.4.5 South America
    • 5.4.5.1 Brazil
    • 5.4.5.2 Argentina
    • 5.4.5.3 Rest of South America

6. Competitive Landscape

  • 6.1 Market Concentration
  • 6.2 Market Share Analysis
  • 6.3 Company Profiles (includes Global-level Overview, Market-level Overview, Core Segments, Financials as available, Strategic Information, Market Rank/Share, Products & Services, Recent Developments)
    • 6.3.1 Abbott Laboratories
    • 6.3.2 AbbVie Inc.
    • 6.3.3 Cadila Pharmaceuticals
    • 6.3.4 Evoke Pharma
    • 6.3.5 AstraZeneca plc
    • 6.3.6 Neurogastrx Inc.
    • 6.3.7 Bausch Health
    • 6.3.8 Theravance Biopharma
    • 6.3.9 GlaxoSmithKline plc
    • 6.3.10 Takeda Pharmaceutical Co.
    • 6.3.11 CinDome Pharma
    • 6.3.12 RaQualia Pharma
    • 6.3.13 SEBELA Pharmaceuticals
    • 6.3.14 TEVA Pharmaceutical
    • 6.3.15 Johnson & Johnson (Janssen)
    • 6.3.16 Pfizer Inc.
    • 6.3.17 Sun Pharma
    • 6.3.18 Lupin Ltd.
    • 6.3.19 Zeria Pharmaceutical
    • 6.3.20 ANI Pharmaceuticals

7. Market Opportunities & Future Outlook

  • 7.1 White-space & Unmet-need Assessment
You Can Purchase Parts Of This Report. Check Out Prices For Specific Sections
Get Price Break-up Now

Global Gastroparesis Drug Market Report Scope

As per the scope of the report, gastroparesis drug is a medication to treat gastroparesis disorder, which in other names means 'stomach paralysis.' It affects the stomach muscles, leading to restriction of proper digestion and causing vomiting and problems related to blood sugar-related problems. The Gastroparesis Drug Market is Segmented by Drug Class (Antiemetic Agents, Prokinetic Agents, and Botulinum Toxin Injections), Disease Type (Diabetic Gastroparesis, Post-Surgical Gastroparesis, Idiopathic Gastroparesis, and Other Disease Types), End User (Hospitals, Clinics, and Pharmacies), and Geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America). The market report also covers the estimated market sizes and trends for 17 countries across major global regions. The report offers the value (in USD million) for the above segments.

By Drug Class Antiemetic Agents 5-HT3 Antagonists
NK-1 Antagonists
Dopamine Antagonists
Prokinetic Agents Metoclopramide
Domperidone
Macrolide Antibiotics
Ghrelin Receptor Agonists
Botulinum Toxin Injections
Others
By Disease Type Diabetic Gastroparesis
Post-Surgical Gastroparesis
Idiopathic Gastroparesis
Viral & Neurological-Induced Gastroparesis
Others
By End User Hospitals
Specialty Clinics
Pharmacies
By Geography North America United States
Canada
Mexico
Europe Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle East & Africa GCC
South Africa
Rest of Middle East & Africa
South America Brazil
Argentina
Rest of South America
By Drug Class
Antiemetic Agents 5-HT3 Antagonists
NK-1 Antagonists
Dopamine Antagonists
Prokinetic Agents Metoclopramide
Domperidone
Macrolide Antibiotics
Ghrelin Receptor Agonists
Botulinum Toxin Injections
Others
By Disease Type
Diabetic Gastroparesis
Post-Surgical Gastroparesis
Idiopathic Gastroparesis
Viral & Neurological-Induced Gastroparesis
Others
By End User
Hospitals
Specialty Clinics
Pharmacies
By Geography
North America United States
Canada
Mexico
Europe Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle East & Africa GCC
South Africa
Rest of Middle East & Africa
South America Brazil
Argentina
Rest of South America
Need A Different Region or Segment?
Customize Now

Key Questions Answered in the Report

What is the current Global Gastroparesis Drug Market size?

The gastroparesis drugs market size reached USD 5.03 billion in 2025.

Who are the key players in Global Gastroparesis Drug Market?

Evoke Pharma, AstraZeneca, Cadila Pharmaceuticals, Neurogastrx, Inc. and AbbVie Inc. ( Allergan Plc) are the major companies operating in the Global Gastroparesis Drug Market.

Why is Asia-Pacific the fastest-growing region?

A surge in diabetes prevalence and expanding diagnostic capacity are driving a 6.41% CAGR in Asia-Pacific through 2030.

Which drug class leads the gastroparesis drugs market?

Prokinetic agents led with a 42.35% share in 2024 due to their direct effect on gastric motility.

Page last updated on: June 23, 2025

Global Gastroparesis Drug Market Report Snapshots